Diabetology Ltd.

R&D around oral insulin, long considered the holy grail of diabetes therapy, has seen some encouraging activity recently despite the pullback of prominent players like Novo Nordisk. The Indian generic

Novo Nordisk AS 's full year earnings for 2016 and financial outlook for the coming year were littered with disappointments; and analysts have highlighted that the company is facing the repercussions

Biocon has entered into an agreement with Bristol-Myers Squibb, under which the US multinational holds an exclusive option to further develop and commercialize the Indian firm's prandial oral insulin

The Indian generics firm, Indoco, has outlined a string of new initiatives to build its presence in the growing chronic and lifestyle disease segments, including a new division focused on cardiology a